Objectif TFR : 1ère étape remportée par le nilotinib versus imatinib avec switch précoce vers nilotinib
You don't have permission to view the content
Quels besoins non couverts restent-ils dans la LMC ?
You don't have permission to view the content
Sommaire Mars 2022
You don't have permission to view the content
Sommaire Juin 2022
You don't have permission to view the content
Horizons Hémato – Vol. 12 n°2 – Juin 2022
You don't have permission to view the content
Le kiosque – 2ème trimestre 2022
You don't have permission to view the content
Flash Presse – 2ème trimestre 2022
You don't have permission to view the content
Thrombopénie immunologique : quoi de neuf en 2022 ?
You don't have permission to view the content
Inhibiteurs proximaux du complément et HPN
You don't have permission to view the content
Eltrombopag et aplasie médullaire sévère
You don't have permission to view the content
French 
English 
